Last updated: September 26, 2026
Hydrocortisone probutate is a mature topical corticosteroid with limited commercial scale, no meaningful biologic or biosimilar exposure, and largely expired originator exclusivity. Its market value is driven by generic availability, dermatology prescribing patterns, reimbursement, and the continued use of topical corticosteroids for inflammatory skin diseases. Public companies do not report hydrocortisone probutate revenue as a separate product line, preventing a precise product-level financial forecast. The commercial outlook is stable to declining, with pricing pressure and substitution from other topical corticosteroids limiting upside.
What is hydrocortisone probutate used to treat?
Hydrocortisone probutate is a synthetic topical corticosteroid used to relieve inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The branded product Pandel Cream contains hydrocortisone probutate 0.1% and is indicated for conditions including atopic dermatitis, contact dermatitis, seborrheic dermatitis, and other steroid-responsive inflammatory skin disorders.[1]
The product is applied topically and is not systemically administered for routine dermatologic use. As with other topical corticosteroids, labeling limits prolonged use, extensive-area application, occlusion, and use in pediatric patients because absorption can increase under those conditions.[1]
| Attribute |
Hydrocortisone probutate |
| Drug class |
Topical corticosteroid |
| Strength commonly marketed |
0.1% |
| Primary dosage form |
Cream |
| Reference product |
Pandel Cream |
| Main therapeutic area |
Inflammatory dermatoses |
| FDA pathway |
Prescription drug approval |
| Biosimilar exposure |
None |
| Main substitutes |
Hydrocortisone butyrate, hydrocortisone valerate, triamcinolone acetonide, desonide, mometasone furoate and other topical corticosteroids |
Hydrocortisone probutate is generally positioned above low-potency over-the-counter hydrocortisone products in clinical intensity, although the practical potency of a topical corticosteroid depends on concentration, vehicle, skin site, disease state, and duration of treatment. Product selection is therefore not based solely on the active ingredient.
When did hydrocortisone probutate lose exclusivity?
Hydrocortisone probutate is a legacy small-molecule topical drug. Its original product exclusivity and any relevant composition-of-matter protection expired years ago. The commercial issue is therefore not loss of a near-term patent cliff. It is the gradual erosion of an older prescription product through generic substitution, product discontinuations, lower reimbursement, and competition from therapeutically similar corticosteroids.
The original Pandel product was approved in the 1990s. Its original regulatory exclusivity has long expired, and any historic patent protection would not normally block generic development today. The FDA Orange Book remains the controlling source for current patent and exclusivity listings, while DailyMed provides current product labeling and marketing information.[1][2]
What is the Orange Book status of hydrocortisone probutate?
Hydrocortisone probutate does not have a meaningful active-patent profile comparable with newer branded dermatology products. The Orange Book should be checked for the current status of any listed hydrocortisone probutate product, but the commercial position is consistent with a mature product whose principal barriers are manufacturing, formulation development, regulatory filing costs, and market access rather than unexpired basic patents.[2]
No active biosimilar framework applies. Hydrocortisone probutate is a small molecule, so competitors would generally pursue an abbreviated new drug application rather than a biosimilar application.
How large is the hydrocortisone probutate market?
The market is niche within the broader topical corticosteroid category. Hydrocortisone probutate competes with a large number of prescription and nonprescription products, including:
- Hydrocortisone 1% and 2.5%
- Hydrocortisone butyrate
- Hydrocortisone valerate
- Desonide
- Triamcinolone acetonide
- Betamethasone dipropionate
- Mometasone furoate
- Fluocinonide
- Clobetasol propionate
The largest commercial pressure comes from products with comparable clinical utility, broader formulary coverage, lower prices, or more familiar prescribing histories. Physicians can often switch among topical corticosteroid strengths and vehicles based on body site, disease severity, patient age, and payer restrictions.
No authoritative public source reports global or U.S. sales for hydrocortisone probutate as a standalone molecule. Manufacturers typically aggregate topical dermatology revenue into broader portfolios. Prescription volume may therefore remain meaningful while product revenue stays modest because generic and contract-manufactured versions carry low unit prices.
What drives demand for hydrocortisone probutate?
Demand is supported by several factors:
- Persistent prevalence of atopic dermatitis, contact dermatitis, eczema, and other inflammatory skin diseases.
- Continued use of topical corticosteroids as first-line treatment.
- Low treatment complexity compared with systemic immunomodulators.
- Familiarity among dermatologists and primary-care prescribers.
- Availability of cream-based treatment for localized lesions.
Demand is constrained by:
- Generic price competition.
- Substitution by lower-cost corticosteroids.
- Increased use of topical calcineurin inhibitors and newer nonsteroidal agents.
- Safety concerns involving prolonged corticosteroid exposure.
- Patient adherence problems associated with topical application.
- Formulary preference for cheaper products with equivalent therapeutic positioning.
What is the financial trajectory of hydrocortisone probutate?
The financial trajectory is best characterized as mature, low-growth, and price-sensitive. Revenue likely peaked during the branded-product period and declined as exclusivity expired and competing topical corticosteroids became widely available. Current revenue is likely distributed across generic manufacturers, wholesalers, pharmacies, and specialty dermatology suppliers rather than concentrated in a high-growth branded franchise.
| Financial factor |
Expected effect |
| Generic entry |
Reduces average selling price and branded share |
| Low manufacturing complexity |
Encourages supplier competition |
| Cream dosage form |
Supports broad distribution but offers limited differentiation |
| Dermatology demand |
Provides recurring baseline volume |
| Formulary control |
Increases substitution and rebate pressure |
| New nonsteroidal therapies |
Limits long-term prescription growth |
| Lack of patent exclusivity |
Reduces pricing power |
| Limited public reporting |
Prevents reliable standalone revenue calculation |
Public-company filings generally do not identify hydrocortisone probutate revenue separately. Any product-level estimate based on corporate dermatology sales would therefore be indirect and subject to substantial allocation error. The more defensible conclusion is that the product is commercially established but not a material growth asset for a large pharmaceutical company.
Which companies are challenging or competing with hydrocortisone probutate?
Competition comes from both generic hydrocortisone probutate suppliers and manufacturers of alternative topical corticosteroids. The competitive landscape is fragmented because topical corticosteroids are available across many potency classes and dosage forms.
Direct competition
Direct competitors would include manufacturers marketing hydrocortisone probutate cream under generic or authorized-generic labels. Their principal advantages are:
- Lower acquisition cost.
- Established FDA regulatory pathways.
- Familiar cream formulation.
- Potential substitution at the pharmacy level where state law and payer policy permit it.
The number and commercial significance of direct generic suppliers can change over time because topical products may be discontinued, periodically unavailable, or commercially unattractive at low prices.
Therapeutic competition
Therapeutic competitors include hydrocortisone butyrate and hydrocortisone valerate, which have similar clinical positioning, and triamcinolone acetonide, which is widely used across multiple inflammatory dermatologic indications. Nonsteroidal alternatives include tacrolimus, pimecrolimus, crisaborole, and newer topical agents used in atopic dermatitis.
The competitive decision is often made at the class level rather than the molecule level. A payer may prefer triamcinolone or generic hydrocortisone because of cost, while a physician may choose a different corticosteroid based on potency, body location, formulation, or patient response.
What patents protect hydrocortisone probutate?
The original active-ingredient and product patents associated with hydrocortisone probutate are not a current commercial barrier. No widely recognized unexpired patent estate gives hydrocortisone probutate a durable monopoly comparable with recently launched dermatology drugs.
Are formulation patents a meaningful barrier?
Formulation patents could theoretically cover:
- Cream vehicle composition.
- Emulsion stability.
- Particle size or dispersion.
- Preservative systems.
- Packaging.
- Enhanced delivery through the stratum corneum.
- Manufacturing processes for uniform drug distribution.
For a mature topical corticosteroid, these rights would need to provide a meaningful clinical or manufacturing advantage to support premium pricing. Routine cream formulations generally offer weak differentiation because competitors can design around vehicle claims and file abbreviated applications based on pharmaceutical equivalence.
Are method-of-use patents relevant?
Method-of-use patents could cover treatment of a particular dermatosis, patient population, treatment duration, or administration protocol. Their commercial value is limited where the active ingredient already has broad dermatologic use and prescribers can use alternative corticosteroids. The practical enforceability of method-of-use rights also depends on labeling, pharmacy substitution, physician behavior, and the ability to prove induced infringement.
Are there Paragraph IV challenges to hydrocortisone probutate?
A Paragraph IV challenge is unlikely to be a central current market event because the key exclusivity period for hydrocortisone probutate has already elapsed. Paragraph IV certifications matter when a generic applicant seeks approval before expiration of an Orange Book-listed patent. For a legacy product with expired basic protection, generic applicants would more likely rely on a certification that no relevant patent blocks approval or that listed patents have expired.
The existence of a generic filing does not guarantee launch. A company may obtain approval but decline commercial distribution because of small market size, manufacturing costs, low reimbursement, supply constraints, or competition from established topical corticosteroids.
What is the FDA regulatory status of hydrocortisone probutate?
Hydrocortisone probutate has an established prescription-drug regulatory history in the United States. The reference product labeling identifies the active ingredient, strength, dosage form, indications, warnings, precautions, and directions for use.[1]
Regulatory requirements for a generic topical product include pharmaceutical equivalence and evidence supporting therapeutic equivalence under the applicable FDA pathway. Topical products can present more development complexity than simple oral tablets because vehicle composition, rheology, particle distribution, and local drug delivery can affect performance.
FDA guidance for topical products recognizes the importance of demonstrating equivalence through a combination of formulation, in vitro performance, and, when required, clinical or pharmacodynamic evidence.[3] These requirements can create a moderate development barrier even when patent protection is absent.
What manufacturing and intellectual-property barriers exist?
Hydrocortisone probutate does not require biologic manufacturing, cold-chain distribution, or complex sterile processing. The manufacturing profile is therefore less demanding than injectable, ophthalmic, or biologic products.
The main technical barriers are:
- Consistent dispersion of the active ingredient.
- Emulsion stability over shelf life.
- Uniformity of dosage across the container.
- Control of viscosity and spreadability.
- Preservation against microbial contamination.
- Packaging compatibility.
- Batch-to-batch equivalence.
- Demonstration of comparable local delivery.
These barriers are manageable for established topical manufacturers but can be material for smaller entrants. They protect execution quality more than they create durable monopoly rights.
How does hydrocortisone probutate compare with newer dermatology drugs?
Hydrocortisone probutate has lower pricing power and less strategic value than newer branded dermatology products with active patents, differentiated mechanisms, or premium reimbursement.
| Category |
Hydrocortisone probutate |
Newer targeted dermatology drugs |
| Mechanism |
Broad corticosteroid anti-inflammatory activity |
Often selective immunologic or nonsteroidal mechanisms |
| Patent position |
Mature or expired |
Frequently active |
| Pricing |
Generic or low branded pricing |
Often premium |
| Reimbursement |
Broad but price-sensitive |
More restricted and authorization-driven |
| Market growth |
Stable to declining |
May grow with disease expansion |
| Safety positioning |
Local steroid risks |
Product-specific safety profile |
| Commercial differentiation |
Limited |
Often based on mechanism, convenience, or evidence |
Newer agents can expand treatment options, but hydrocortisone probutate retains a role where low acquisition cost, rapid anti-inflammatory activity, and physician familiarity are priorities.
What generic launch risks exist?
A new generic launch would face limited legal risk but meaningful commercial risk. The principal risks are:
- Insufficient prescription volume.
- Price erosion after multiple suppliers enter.
- Payer preference for alternative corticosteroids.
- Difficulty obtaining profitable pharmacy placement.
- Manufacturing interruptions.
- Product discontinuation by the reference or generic manufacturer.
- Low physician awareness of the specific molecule.
- Competition from cheaper therapeutically equivalent products.
A plausible launch scenario is a low-price generic entering selectively through wholesalers and payer contracts, followed by rapid margin compression. A less favorable scenario is regulatory approval without sustained marketing because the addressable market cannot support promotional or manufacturing investment.
How strong is the hydrocortisone probutate patent estate?
The patent estate is weak as a source of current exclusivity. Its commercial protection is better described as regulatory and operational than patent-based.
| Protection type |
Current strategic value |
| Composition-of-matter patent |
Low or expired |
| Original product patent |
Low or expired |
| Formulation patent |
Potentially limited and design-around risk |
| Method-of-use patent |
Narrow practical value |
| FDA exclusivity |
Expired for the legacy product |
| Manufacturing know-how |
Moderate operational value |
| Brand recognition |
Limited but potentially useful |
| Distribution relationships |
Potentially more important than patents |
What licensing deals affect hydrocortisone probutate?
No major recent licensing transaction has publicly established hydrocortisone probutate as a strategic growth asset. Historical ownership and commercialization arrangements may have transferred between dermatology companies, but the product’s mature status limits the likelihood of a large standalone licensing deal.
Potential transaction value would depend on portfolio fit rather than on hydrocortisone probutate alone. A buyer could acquire the product as part of a broader dermatology portfolio containing multiple topical medicines, established sales channels, or manufacturing capacity.
Key Takeaways
- Hydrocortisone probutate is a mature topical corticosteroid with limited standalone commercial scale.
- Pandel is the historical reference product, with hydrocortisone probutate 0.1% cream as the principal dosage form.
- Original exclusivity has expired, and the current market is primarily shaped by generic substitution and therapeutic alternatives.
- No biosimilar risk applies because hydrocortisone probutate is a small molecule.
- Formulation and manufacturing know-how matter more than active patent protection.
- Public companies do not generally disclose hydrocortisone probutate revenue separately.
- The financial trajectory is likely stable to declining, with low pricing power and limited growth potential.
- Generic entry is legally feasible but commercially difficult because of low margins and strong class-level competition.
- Newer nonsteroidal dermatology products can pressure demand, but low-cost corticosteroid therapy remains clinically relevant.
FAQs About Hydrocortisone Probutate
Is hydrocortisone probutate the same as hydrocortisone?
No. Hydrocortisone probutate is a chemically modified topical corticosteroid. It is different from standard hydrocortisone and is generally used as a prescription-strength topical anti-inflammatory product.
Is hydrocortisone probutate available over the counter?
Hydrocortisone probutate is generally treated as a prescription active ingredient in the United States. Over-the-counter hydrocortisone products use different strengths and regulatory formulations.
Does hydrocortisone probutate have biosimilar competition?
No. Biosimilars apply to biologic products. Hydrocortisone probutate is a small molecule, so competition occurs through generic drug applications.
Why might a hydrocortisone probutate generic be discontinued?
Low sales, price erosion, manufacturing costs, supply-chain problems, and payer preference for other topical corticosteroids can make continued commercialization uneconomic.
Can hydrocortisone probutate support a premium dermatology franchise?
Usually not as a standalone product. Its commercial value is more likely to arise from inclusion in a broader dermatology portfolio with multiple products, shared manufacturing, and established distribution.
References
-
DailyMed. (n.d.). Pandel: Hydrocortisone probutate cream, 0.1% prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2022). Draft guidance for industry: Topical dermatologic corticosteroids: In vitro release test studies. https://www.fda.gov/ рег
